Small biotechs in early development of cell therapies are often surprised by the strictness of commercial manufacturing standards. That’s the view of Luděk Sojka, PhD, CEO of contract developer and ...
CRISPR-Cas9 is one of the most commonly leveraged non-viral editing tools to engineer cells for therapeutics applications. It is a nuclease-based genome editing system which has seen exponential ...
Applied StemCell, Inc. (“ASC”), a genome engineering company with deep expertise in induced pluripotent stem cell (iPSC) ...
Exogenus Therapeutics Taps Lonza to Develop a GMP-Compliant Process for Lead Exosome-Based Candidate
Exogenus Therapeutics and Lonza agreed to collaborate on the development of Exo-101, Exogenus’ exosome-based lead candidate. The company specializes in the development of therapeutics based on ...
In today’s fast-paced biopharmaceutical industry, accelerating microbial process development is critical for moving from gene to GMP with greater speed and efficiency. This webinar will highlight ...
Eurofins CDMO Amatsiaquitaine S.A.S., the GMP manufacturer, to support Polyrizon in future commercialization efforts Raanana, Israel, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (PLRZ) (the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results